JP2007289187A5 - - Google Patents

Download PDF

Info

Publication number
JP2007289187A5
JP2007289187A5 JP2007107978A JP2007107978A JP2007289187A5 JP 2007289187 A5 JP2007289187 A5 JP 2007289187A5 JP 2007107978 A JP2007107978 A JP 2007107978A JP 2007107978 A JP2007107978 A JP 2007107978A JP 2007289187 A5 JP2007289187 A5 JP 2007289187A5
Authority
JP
Japan
Prior art keywords
xaa
peptide
cys
leu
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007107978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007289187A (ja
JP5004640B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007289187A publication Critical patent/JP2007289187A/ja
Publication of JP2007289187A5 publication Critical patent/JP2007289187A5/ja
Application granted granted Critical
Publication of JP5004640B2 publication Critical patent/JP5004640B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007107978A 1999-12-24 2007-04-17 生理活性化合物の消失半減期延長のための方法及び組成物 Expired - Lifetime JP5004640B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17304899P 1999-12-24 1999-12-24
US60/173,048 1999-12-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001546685A Division JP2003518075A (ja) 1999-12-24 2000-12-22 生理活性化合物の消失半減期延長のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2007289187A JP2007289187A (ja) 2007-11-08
JP2007289187A5 true JP2007289187A5 (OSRAM) 2007-12-20
JP5004640B2 JP5004640B2 (ja) 2012-08-22

Family

ID=22630310

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001546685A Pending JP2003518075A (ja) 1999-12-24 2000-12-22 生理活性化合物の消失半減期延長のための方法及び組成物
JP2007107978A Expired - Lifetime JP5004640B2 (ja) 1999-12-24 2007-04-17 生理活性化合物の消失半減期延長のための方法及び組成物
JP2007154102A Expired - Lifetime JP4949132B2 (ja) 1999-12-24 2007-06-11 生理活性化合物の消失半減期延長のための方法及び組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001546685A Pending JP2003518075A (ja) 1999-12-24 2000-12-22 生理活性化合物の消失半減期延長のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007154102A Expired - Lifetime JP4949132B2 (ja) 1999-12-24 2007-06-11 生理活性化合物の消失半減期延長のための方法及び組成物

Country Status (12)

Country Link
US (3) US7608681B2 (OSRAM)
EP (2) EP2180054A1 (OSRAM)
JP (3) JP2003518075A (OSRAM)
AT (2) ATE337403T1 (OSRAM)
AU (3) AU784285B2 (OSRAM)
CA (2) CA2390691C (OSRAM)
CY (1) CY1106236T1 (OSRAM)
DE (2) DE60041564D1 (OSRAM)
DK (1) DK1240337T3 (OSRAM)
ES (1) ES2270893T3 (OSRAM)
PT (1) PT1240337E (OSRAM)
WO (1) WO2001045746A2 (OSRAM)

Families Citing this family (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022112A1 (en) 1998-10-13 2000-04-20 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
DE60041564D1 (de) * 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
EP1332158B1 (de) * 2000-11-08 2007-08-01 Fresenius Medical Care Affina GmbH Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
WO2003106493A1 (en) * 2002-06-14 2003-12-24 Dyax Corporation Protein analysis
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DE60305919T2 (de) * 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
EP2275448A3 (en) 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
CN1950394B (zh) 2004-03-10 2014-04-02 三一治疗公司 在受试者中抑制免疫复合物形成的方法
AU2011253771B2 (en) * 2004-03-10 2013-10-31 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subject
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
BRPI0511755A (pt) * 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
KR20070086896A (ko) * 2004-12-02 2007-08-27 도만티스 리미티드 항­il­1r1 단일 도메인 항체 및 치료적 용도
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
RU2007119989A (ru) * 2004-12-02 2009-01-10 Домантис Лимитед (Gb) Композиции, слитые конструкции и конъюгаты plad домена
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20090105138A1 (en) * 2005-09-06 2009-04-23 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
US20100015146A1 (en) * 2005-10-14 2010-01-21 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
RU2470941C2 (ru) 2005-12-02 2012-12-27 Дженентек, Инк. Связывающие полипептиды и их применения
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
EP1996617A2 (en) 2006-03-15 2008-12-03 Novo Nordisk A/S Amylin derivatives
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US20100129368A9 (en) * 2006-10-11 2010-05-27 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
CA2672386A1 (en) * 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
BRPI0720552A2 (pt) 2006-12-19 2014-01-07 Genentech Inc Antagonistas específicos de vegf para terapia adjuvante e neoadjuvante e o tratamento de tumores em estágio precoce
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
RS53595B1 (sr) 2007-07-16 2015-02-27 Genentech, Inc. Anti-cd79b antitela i imunokonjugati i metode upotrebe
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
ES2346178T3 (es) 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
KR100920729B1 (ko) * 2007-10-01 2009-10-07 한국생명공학연구원 펩타이드 혼성체를 사용한 배향성이 조절된 항체단분자막의 제조방법
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
MX2010012518A (es) 2008-05-16 2010-12-06 Ablynx Nv Secuencias de aminoacidos dirigidas contra cxcr4 y otros receptores acoplados a proteina g y compuestos que comprenden los mismos.
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP3130603A1 (en) 2008-06-30 2017-02-15 ESBATech, an Alcon Biomedical Research Unit LLC Functionalized polypeptides
CN104800147A (zh) 2008-07-10 2015-07-29 德勒尼克斯治疗股份公司 用于大分子的增强的递送的方法和组合物
BRPI0915968B1 (pt) 2008-07-18 2021-11-23 Trinity Therapeutics, inc Uso de polipeptídeo purificado para tratar infecção pelo vírus da dengue
CN102164965B (zh) 2008-09-26 2016-03-30 Ucb医药有限公司 生物产品
CN102197049B (zh) 2008-10-21 2015-03-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
US20100143351A1 (en) 2008-11-22 2010-06-10 Genentech, Inc. Anti-Angiogenesis Therapy for the Treatment of Breast Cancer
CN102257003B (zh) 2008-12-19 2017-04-05 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8754035B2 (en) * 2009-02-26 2014-06-17 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
SG174904A1 (en) 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
KR20130119990A (ko) 2009-04-10 2013-11-01 아블린쓰 엔.브이. Il-6r에 대한 개선된 아미노산 서열 및 il-6r 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
CA2764398A1 (en) 2009-06-05 2010-12-09 Erik Depla Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
JP6088246B2 (ja) 2009-08-15 2017-03-01 ジェネンテック, インコーポレイテッド 以前に治療された乳癌の治療のための抗血管新生療法
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AU2010310585A1 (en) 2009-10-22 2012-05-03 Genentech, Inc. Anti-hepsin antibodies and methods using same
CA2780143A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CN103237810A (zh) 2010-02-23 2013-08-07 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
HRP20130953T1 (hr) 2010-04-15 2013-11-22 Spirogen Sàrl Pirolobenzodiazepini i njihovi konjugati
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
AU2011261362B2 (en) 2010-06-03 2016-06-09 Genentech, Inc. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2540114T3 (es) 2010-07-09 2015-07-08 Affibody Ab Polipéptidos
EP2621538B1 (en) 2010-09-28 2015-12-16 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
ES2723775T3 (es) 2010-11-08 2019-09-02 Ablynx Nv Polipéptidos que se unen a CXCR2
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
KR101782790B1 (ko) 2010-11-26 2017-09-28 몰리큘라 파트너스 아게 혈청 알부민에 결합하는 설계된 반복 단백질
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
BR112013030298A2 (pt) 2011-05-27 2017-12-12 Ablynx Nv inibição da reabsorção óssea com peptídeos que se ligam ao rankl
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン.ヴェー. IgEに対する免疫グロブリン単一可変ドメイン
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
MX2014000316A (es) 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
EP2749646B1 (en) 2011-08-24 2018-03-21 Kagoshima University IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
CA2849409A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Anti-tumor necrosis factor-alpha agents and uses thereof
JP6219287B2 (ja) 2011-09-30 2017-10-25 アブリンクス エン.ヴェー. c−Metに関連する生物学的物質
PL2750713T3 (pl) 2011-10-14 2016-03-31 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
BR112014011304B1 (pt) 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
EP2820047B1 (en) * 2012-03-01 2018-04-25 Amgen Research (Munich) GmbH Long life polypeptide binding molecules
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
ES2670442T3 (es) 2012-05-25 2018-05-30 Janssen Biotech, Inc. Dominios de unión a albúmina de consenso no naturales
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
JP6152379B2 (ja) * 2012-06-29 2017-06-21 旭化成メディカル株式会社 プロテインaのbドメイン変異体を含むポリペプチドが結合された担体からなる吸着材
JP6590695B2 (ja) 2012-09-25 2019-10-16 アフィボディ・アーベー アルブミン結合ポリペプチド
PL2906251T3 (pl) 2012-10-12 2018-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
DK2906253T3 (en) 2012-10-12 2018-10-22 Adc Therapeutics Sa Pyrrolobenzodiazepine anti-PSMA antibody conjugates
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
WO2014057119A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
CN110256469B (zh) 2012-10-12 2022-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
AU2013336646B2 (en) 2012-10-25 2016-07-14 Affibody Ab ABD binding polypeptide
JP6396303B2 (ja) 2012-10-25 2018-09-26 アフィボディ・アーベー アルブミン結合を含有するタンパク質の分離方法
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
EP2752426A1 (en) 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof
EP2949750B1 (en) 2013-01-28 2019-11-13 National Institute of Advanced Industrial Science and Technology Antibody-binding peptide
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック, インコーポレイテッド 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
CN107106700B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
WO2015132248A2 (en) * 2014-03-03 2015-09-11 Vrije Universiteit Brussel (Vub) Sequamers - a novel non-natural type of peptide libraries randomly constrained by their primary sequences
WO2015139046A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
EP2940128A1 (en) * 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
KR102546875B1 (ko) * 2014-05-02 2023-06-26 모멘타 파머슈티컬스 인코포레이티드 공학처리된 fc 작제물과 관련된 조성물 및 방법
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック, インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3388449A3 (en) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
KR20170067771A (ko) 2014-09-17 2017-06-16 제넨테크, 인크. 피롤로벤조디아제핀 및 이의 항체 디설파이드 컨주게이트
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
KR20170080675A (ko) 2014-11-05 2017-07-10 제넨테크, 인크. 항-fgfr2/3 항체 및 이의 이용 방법
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
KR102833432B1 (ko) 2014-12-19 2025-07-14 이노자임 파마, 인코포레이티드 조직 석회화의 치료 방법
WO2016156570A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
EP3277811B1 (en) 2015-04-03 2020-12-23 University of Massachusetts Fully stabilized asymmetric sirna
MX387517B (es) 2015-04-06 2025-03-18 Subdomain Llc Polipeptidos que contienen dominios de union de novo y usos de los mismos.
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
PL3294319T3 (pl) 2015-05-13 2024-10-07 Ablynx Nv Polipeptydy rekrutujące komórki t na podstawie reaktywności cd3
LT3611192T (lt) 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
CA2995110A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
RU2694050C1 (ru) * 2015-10-23 2019-07-09 Фуджифилм Корпорэйшн Циклический пептид, подложка для аффинной хроматографии, меченое антитело, конъюгат антитела и лекарственного средства и фармацевтический препарат
BR112018010802A2 (pt) 2015-11-27 2018-11-27 Ablynx Nv polipeptídeos que inibem cd40l
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
WO2017132669A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109153711B (zh) 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
JP6985289B2 (ja) 2016-04-15 2021-12-22 バークレー ライツ,インコーポレイテッド ペン内アッセイの方法、システム及びキット
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
NZ749279A (en) 2016-05-23 2025-08-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
UA126021C2 (uk) * 2016-06-03 2022-08-03 Янссен Байотек, Інк. Домен фібронектину типу ііі, що зв'язується із сироватковим альбуміном
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11753638B2 (en) 2016-08-12 2023-09-12 University Of Massachusetts Conjugated oligonucleotides
WO2018043629A1 (ja) 2016-09-01 2018-03-08 国立研究開発法人産業技術総合研究所 非天然型立体構造を形成した抗体に親和性を示すポリペプチド
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
BR112019006301A2 (pt) 2016-09-30 2019-07-30 Fujifilm Corp peptídeo cíclico, suporte de cromatografia de afinidade, anticorpo marcado, conjugado anticorpo - fármaco, e preparação farmacêutica
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018089702A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
IL266506B2 (en) 2016-11-16 2025-05-01 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
US11220531B2 (en) 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
BR112019016373B1 (pt) 2017-02-08 2022-01-25 Medimmune Limited Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー/エス オリゴマー伸長インスリン−Fcコンジュゲート
ES2926144T3 (es) 2017-04-18 2022-10-24 Medimmune Ltd Conjugados de pirrolobenzodiazepina
JP7408396B2 (ja) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
WO2018199337A1 (ja) 2017-04-28 2018-11-01 味の素株式会社 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
US12129308B2 (en) 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
EP3630817A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Polypeptides binding adamts5, mmp13 and aggrecan
KR102752550B1 (ko) 2017-06-02 2025-01-10 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
PL3638373T3 (pl) 2017-06-14 2025-04-14 Adc Therapeutics Sa Schematy dawkowania dla podawania ADC anty-CD19
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF
AU2018313253B2 (en) 2017-08-11 2024-09-26 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
EP3668874B1 (en) 2017-08-18 2021-12-22 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
EP3694873A1 (en) 2017-10-10 2020-08-19 Numab Therapeutics AG Multispecific antibody
EP3721209B1 (en) 2017-10-15 2024-02-07 Berkeley Lights, Inc. Methods for in-pen assays
CA3082410A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. Multifunctional immune cell therapies
EA202091198A1 (ru) 2017-11-14 2020-09-09 Эрселлкс, Инк. Полипептиды, содержащие домен d, и их применение
WO2019107962A2 (ko) * 2017-11-29 2019-06-06 아주대학교 산학협력단 항체와 생리활성물질의 접합방법
KR102037336B1 (ko) * 2017-11-29 2019-10-29 아주대학교산학협력단 항체와 생리활성물질의 접합방법
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN120665147A (zh) 2018-06-14 2025-09-19 味之素株式会社 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
KR20210022004A (ko) 2018-06-18 2021-03-02 안위타 바이오사이언시스, 인코포레이티드 항-메소텔린 작제물 및 이의 용도
JP7618229B2 (ja) 2018-08-10 2025-01-21 ユニバーシティー オブ マサチューセッツ Snpを標的化する修飾オリゴヌクレオチド
JP7627042B2 (ja) 2018-08-23 2025-02-05 ユニバーシティー オブ マサチューセッツ O-メチルリッチ完全安定化オリゴヌクレオチド
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CN113227124B (zh) 2018-10-31 2025-04-08 味之素株式会社 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック, インコーポレイテッド Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
EP3898701A4 (en) 2018-12-20 2022-10-26 Kleo Pharmaceuticals, Inc. COMBINATION THERAPY OF WEAPONS AND NATURAL KILLER CELLS
CN113614232A (zh) * 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
US12024706B2 (en) 2019-08-09 2024-07-02 University Of Massachusetts Modified oligonucleotides targeting SNPs
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP4076505A4 (en) 2019-12-18 2024-01-24 ARO Biotherapeutics Company SERUM ALBUM BINDING FIBRONECTIN TYPE III DOMAIN AND USES THEREOF
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
KR20220166788A (ko) 2020-03-09 2022-12-19 버클리 라잇츠, 인크. 펜내 분석을 위한 방법, 시스템 및 키트
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
TW202216174A (zh) 2020-06-30 2022-05-01 日商蓋亞生物製藥有限公司 使nk細胞與抗體之結合穩定化之方法及其利用
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
KR20230166075A (ko) 2021-02-02 2023-12-06 누맙 세러퓨틱스 아게 Ror1 및 cd3에 대한 특이성을 가지는 다중 특이적 항체
IL305301A (en) 2021-02-19 2023-10-01 Us Health SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
IL306096A (en) 2021-03-26 2023-11-01 Arcellx Inc Multifunctional immune cell therapies
TW202315943A (zh) 2021-06-23 2023-04-16 麻薩諸塞大學 用於治療子癇前症及其它血管新生病症的最佳化抗flt1寡核苷酸化合物
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
EP4488290A1 (en) 2022-03-04 2025-01-08 ABTIS Co., Ltd. Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive
EP4534547A1 (en) 2022-06-02 2025-04-09 Ajinomoto Co., Inc. Affinity substance, compound, and antibody and their salts
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
IL319526A (en) 2022-09-30 2025-05-01 Extend Biosciences Inc Long-acting parathyroid hormone
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
AU2024277146A1 (en) * 2023-05-22 2025-11-27 Kaida Biopharmaceuticals, Inc. Antagonist fusion polypeptides
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
US12377158B1 (en) * 2024-07-05 2025-08-05 Michael Farber Enhanced peptide constructs for albumin binding

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US763829A (en) 1903-01-16 1904-06-28 L E Knott Apparatus Company Apparatus for reading angular deflections.
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (OSRAM) 1974-03-08 1982-06-04
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
EP0429537A4 (en) 1988-08-18 1991-08-21 California Biotechnology, Inc. Atrial natriuretic peptide clearance inhibitors
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2122717C (en) * 1991-11-08 2003-07-15 David C. Anderson Hemoglobins as drug delivery agents
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
ES2233928T3 (es) * 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. Derivados de dolastatina.
US5627263A (en) 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
PT833911E (pt) 1995-06-07 2004-09-30 Ortho Mcneil Pharm Inc Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
EP1027073A2 (en) * 1996-11-19 2000-08-16 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
CA2440582A1 (en) * 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030009395A1 (en) * 2001-07-06 2003-01-09 Yu Philip Shi-Lung Method and apparatus for providing information regarding a product
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
ES2401428T3 (es) * 2002-04-10 2013-04-19 Genentech, Inc. Variantes de anticuerpos anti-HER2
JP3997859B2 (ja) * 2002-07-25 2007-10-24 株式会社日立製作所 半導体装置の製造方法および製造装置
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20040032828A1 (en) * 2002-08-16 2004-02-19 Cellglide Technologies Corp. Service management in cellular networks

Similar Documents

Publication Publication Date Title
JP5004640B2 (ja) 生理活性化合物の消失半減期延長のための方法及び組成物
JP2007289187A5 (OSRAM)
US20070020264A1 (en) Serum albumin binding peptides for tumor targeting
US20140294863A1 (en) Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) Serum albumin binding peptides for tumor targeting
JP2003518075A5 (OSRAM)
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
JP2003503426A (ja) FVIIaアンタゴニスト
AU783087B2 (en) Peptide antagonists of factor VIIA
EP1757311B1 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
US20070173444A1 (en) Peptides and compounds that bind to the il-5 receptor
HK1099199A (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
HK1099043A (en) Methods and compositions for prolonging elimination half-times of bioactive compounds